Solid Biosciences Reports Third-Quarter 2026 Financial Results
Solid Biosciences reported third-quarter 2026 financial results. The supplied body says SGT-003 has been generally well tolerated in 53 participants dosed.
Story updates
09:14:12 PM UTC
SquawkNews
Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 -- Solid has scheduled a Type C meeting with the FDA in late Q4 2026 to discuss the preliminary INSPIRE DUCHENNE SGT-003 data package…
09:14:24 PM UTC
SquawkNews
Solid Biosciences reported $348.9M in cash, cash equivalents and available-for-sale securities as of September 30, 2026, with anticipated runway into H1 2028. SGT-003 has been generally well tolerated in 53 participants dosed; an FDA Type C meeting is scheduled for late Q4 2026.Material DetailsCont…
09:15:43 PM UTC
SquawkNews
Solid Biosciences reported a third-quarter 2026 net loss of $53.9M, compared with a $45.8M loss a year earlier, as operating expenses increased 20% to $57.7M. Diluted loss per share was $0.36, versus $0.48 in the prior-year quarter.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Solid B…